C15 (Pentadecanoic Acid) for Kidney Health
C15 (pentadecanoic acid) is not recommended for improving renal function or preventing kidney disease, as there is no evidence supporting its efficacy for kidney-specific outcomes, and it is not mentioned in current kidney disease management guidelines.
Evidence Assessment
The 2024 KDIGO guidelines 1, 2, 3 provide comprehensive, evidence-based recommendations for CKD management but make no mention of C15 or pentadecanoic acid as a therapeutic intervention for kidney health. These guidelines represent the highest quality evidence for CKD management and should guide clinical decision-making.
What the Guidelines Actually Recommend for Kidney Health:
For CKD progression prevention:
- SGLT2 inhibitors for patients with proteinuria (with or without diabetes)
- RAAS inhibitors for blood pressure control and proteinuria management
- Finerenone for patients with type 2 diabetes and CKD
- GLP-1 receptor agonists for kidney-protective effects 3
For cardiovascular risk reduction in CKD:
- Statins or statin/ezetimibe combinations for adults ≥50 years with eGFR <60 ml/min per 1.73 m² 1, 2
- Mediterranean-style diet as an adjunct to lipid-modifying therapy 1
C15 Research Context
While research on C15 exists 4, 5, 6, 7, 8, these studies focus on:
- Cell-based assays showing anti-inflammatory and antiproliferative activities 5, 6
- Cardiovascular associations (hypertension, cardiometabolic disease) 8
- General metabolic effects 4
Critical limitation: None of these studies directly evaluate C15's effect on kidney function, CKD progression, or kidney-specific outcomes. The research on C15 and kidney health is essentially non-existent.
Why This Matters:
The one study mentioning kidney-related outcomes 9 evaluated probiotics for CKD, not C15. This is entirely unrelated to pentadecanoic acid supplementation.
Clinical Bottom Line
Use evidence-based therapies with proven kidney benefits:
- SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin)
- RAAS inhibitors (ACE inhibitors or ARBs)
- Finerenone for diabetic CKD
- Statins for cardiovascular protection 1, 3
Do not substitute unproven supplements like C15 for guideline-directed medical therapy. The absence of C15 from KDIGO 2024 guidelines—despite their comprehensive review of CKD interventions—speaks volumes about the lack of kidney-specific evidence.
Common Pitfall to Avoid:
Do not extrapolate C15's potential cardiovascular or anti-inflammatory effects to assume kidney benefits. Kidney disease requires interventions with demonstrated effects on renal outcomes (eGFR decline, proteinuria, ESRD progression), which C15 lacks entirely.